Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticonvulsant

or Antidepressant

or Neuroactive steroid

Use the filters below to narrow your results.

None (2) · Agomelatine (1) · Amoxapine (1) · Brivaracetam (1) · Cannabidiol (1) · Cenobamate (1) · Clobazam (1) · Clomipramine (1) · Desipramine (1) · Duloxetine (1) · Eslicarbazepine (1) · Ethosuximide (1) · Felbamate (1) · Fenfluramine (1) · Fosphenytoin (1) · Imipramine (1) · Isocarboxazid (1) · Lacosamide (1) · Levomilnacipran (1) · Maprotiline (1) · Milnacipran (1) · Moclobemide (1) · Nefazodone (1) · Perampanel (1) · Phenelzine (1) · Phenobarbital (1) · Phenytoin (1) · Protriptyline (1) · Reboxetine (1) · Rufinamide (1) · Sertraline (1) · Stiripentol (1) · Tiagabine (1) · Tianeptine (1) · Tranylcypromine (1) · Trimipramine (1) · Valproic acid (1) · Vigabatrin (1) · Zonisamide (1)

None (1) · AMPA receptor antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of phenytoin; sodium channel blocker (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin releaser; sigma-1 agonist (1) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. (1) · T-type calcium channel blocker (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (37) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Postpartum depression (PPD) in adults (1) · Postpartum depression (PPD) in adults (FDA-approved 2023) (1)

None (37) · 25 mg (1) · 50 mg PO once daily with fatty food in the evening × 14 days (1) · Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h (1)

None (37) · 100 mg/20 mL vial, single-use (1) · 20 mg, 25 mg, 30 mg capsules (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)

None (37) · 200 mg/d (1) · 50 mg/d × 14 d (1) · Single 60-hour course (1)

None (36) · Intravenous (continuous infusion in a REMS-certified facility) (1) · Oral (3)

None (36) · Antidepressant effect within hours of infusion start; sustained at 30 days (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Day 3 of dosing in trials; sustained through day 45 (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (36) · 14-day course; effect persists after discontinuation in trials (1) · Chronic daily dosing (1) · Long (1) · Single infusion course (1)

None (36) · ~12 hours (1) · ~16-23 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~9 hours (terminal) (1)

None (36) · 100% (IV) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Adequate (food-dependent, must take with fatty meal) (1) · ~50% (highly variable) (1)

None (36) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Medicine is structurally identical to endogenous allopregnanolone; pregnancy considerations relate to breastfeeding during/after infusion. Limited data; brief interruption of breastfeeding considered (1)

None (36) · Rx, Schedule IV (US) (1) · Rx-only (1) · Rx-only in US (1) · Rx; REMS program required (excessive sedation/loss of consciousness during infusion) (1)